Company profile
BARINTHUS BIOTHERAPEUTICS PLC.
NASDAQ:BRNSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NIVOLUMAB | phase2 | — | 222 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03277456 | — | completed | 2017-09-18 | 2017-11-02 | Barinthus Biotherapeutics | A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 |
| NCT03880474 | phase2 | terminated | 2019-03-18 | 2019-10-15 | Barinthus Biotherapeutics | Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults |
| NCT03883113 | phase2 | completed | 2019-06-03 | 2019-12-16 | Barinthus Biotherapeutics | Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model |
| NCT05343481 | phase2 | completed | 2022-09-21 | 2026-01-13 | Barinthus Biotherapeutics | Efficacy of VTP-300 in Chronic Hepatitis B Infection |
| NCT04297917 | phase1 | completed | 2019-02-10 | 2022-05-23 | Barinthus Biotherapeutics | First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection |
FDA applications (0)
No records yet.